Gilead Sciences Inc., of Foster City Calif., said positive top-line results from a phase III trial evaluating Sovaldi (sofosbuvir) in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection in Japan put it on track for a midyear filing with the Japanese Pharmaceutical and Medical Devices Agency.